As per Future Market Insights’ latest industry analysis, the valuation for the global clinical next-generation sequencing (NGS) data analysis industry size was around US$ 2.3 Billion in 2022, and the market is projected to exhibit growth at a CAGR of 17.4% over the forecast period, with an estimated valuation of around US$ 13.1 Billion by 2033.
Increasing prevalence of cancer, rise in geriatric population and lifestyle diseases globally, technological advancements in the field of genomic-based bioinformatics tools, and increasing government funding for life science projects, are some of the significant factors accelerating the market growth.
The demand for precise and quick sequencing interpretation tools and algorithms that may accelerate data processing is growing as clinical next-generation sequencing (NGS) technology progresses and their usage in clinical diagnosis, genomic research, and personalized treatments for a variety of disorders increases.
Get Recently Updated Report of Market as Sample Copy! https://www.futuremarketinsights.com/reports/sample/rep-gb-16757
It is anticipated that sequencing programs would expand in scope because of rising genetic data production and declining sequencing costs. As a result, there is a higher need for complex bioinformatics pipelines that include state-of-the-art, efficient solutions.
Key Takeaways from Market Study:
- NGS data analysis & sequencing services is the leading segment as solution and services, and is anticipated to hold a CAGR of 15.2% between 2023 & 2033, owing to affordability of NGS data analysis & sequencing services.
- Sequencing by synthesis (SBS) segment by technology holds a market value share of around 42.7% in 2022, because of its capabilities, which include long-insert paired-end reads for efficient sequence assembly, de novo sequencing, and other applications.
- Medical research dominates in term of application of clinical next-generation sequencing (NGS) data analysis with a projected market value share of around 39.6% in 2022, owing to increasing sequencing based approaches.
- By end user, academic & research institutes held a share of around 37.7% in 2022, due to increasing adoption of NGS platforms.
- North America held a value share of around 40.6% in 2022, owing to the advancements made in personalized medicines, NGS, and companion diagnostics in the region.
“The development of next-generation sequencing (NGS) technologies and their increased use in genomic research, clinical diagnosis and personalized treatment for a numerous diseases are driving up the demand for exact and rapid sequencing interpretation tools and algorithms speeding up data analysis, which result in increased market demand,” says an analyst of Future Market Insights.
Get In Touch With Our Analyst To Resolve Any Doubts You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16757
Market Competition:
The COVID-19 pandemic had a favorable effect on the clinical next-generation sequencing (NGS) data analysis industry, due to the increased implementation of next-generation sequencing (NGS) technology. NGS technology was also used to identify new coronavirus strains and other diseases.
The overall demand for the healthcare sector has increased because of the increased demand. In light of the increased demand for COVID-19-related research, the clinical next-generation sequencing (NGS) data analysis market experienced a jump in demand during the height of the pandemic.
- In September 2022, QIAGEN and Neuron23 collaborated to develop next-generation sequencing companion diagnostics for a novel Parkinson’s disease drug.
- In March 2022, Thermo Fisher Scientific launched the Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing (NGS) platform.
Key Companies Profiled:
- Agilent Technologies, Inc.
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- BGI Group
- Qiagen
- Roche Diagnostics
- DNAStar, Inc.
- Bio-Rad Laboratories, Inc.
- Congenica Ltd.
- Theragen Etex Inc.
- PerkinElmer, Inc.
- Partek Inc.
- Oxford Nanopore Technologies PLC.
- Pacific Biosciences of California, Inc.
- Golden Helix, Inc.
- BioDatomics
- PierianDx
Customization Unleashed: Learn How to Stand Out in a Competitive Landscape! https://www.futuremarketinsights.com/customization-available/rep-gb-16757
Key Market Segments Covered in the Clinical Next-Generation Sequencing (NGS) Data Analysis Industry Research:
Solution and Services:
- NGS Data Analysis Tools
- Sequence Alignment Tools
- Alignment Visualization Tools
- Gene Prediction Tools
- Variant Analysis Tools
- Others
- Platforms
- Next-Generation Sequencing (NGS) Platforms
- Clinical Informatics Platforms
- Others
- NGS Data Analysis & Sequencing Services
- Whole-Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Comprehensive genomic profiling (CGP)
- Custom Panels
- RNA Sequencing
- Other Sequencing Services
- NGS Storage, Management & Cloud Computing Platform
Technology:
- Sequencing by Synthesis (SBS)
- Nanopore Sequencing
- Single-Molecule Real-Time (SMRT) Sequencing
- Others
Application:
- Diagnostics
- Drug Discovery & Designing
- Medical Research
- Others
End User:
- Hospitals & Clinics
- Academic Institutes & Research Centers
- Biotechnology Companies
- Life Science Technology Vendors
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube